IGR Blood Cancer Drugs Market 点击阅读
  • 评论

IGR

Blood Cancer Drugs Market

出版日期 / “健康与健身, 商业” / 语言—English / 5页
The report on Blood Cancer Drugs Market by product (rituaxan/mabthera, gleevac/glivec, revlimid, velcade, tasigna, pomalyst, vidaza, kyprolis, adcetris, and others) trends analysis and forecasts up to 2023 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Blood Cancer Drugs Market is projected to grow at a CAGR between 10.5% to 11.5% in terms of value over the period of 更多
显示标签

“ IGR”的其他出版物

查看所有出版物